Neurofilament as a potential biomarker for spinal muscular atrophy by Darras, BT et al.
RESEARCH ARTICLE
Neurofilament as a potential biomarker for spinal muscular
atrophy
Basil T. Darras1, Thomas O. Crawford2,3, Richard S. Finkel4, Eugenio Mercuri5, Darryl C. De Vivo6,
Maryam Oskoui7, Eduardo F. Tizzano8, Monique M. Ryan9, Francesco Muntoni10,11, Guolin Zhao12,
John Staropoli12,*, Alexander McCampbell12, Marco Petrillo12, Christopher Stebbins12,
Stephanie Fradette12, Wildon Farwell12 & Charlotte J. Sumner2,13
1Department of Neurology, Boston Children’s Hospital and Harvard Medical School, Boston, Massachusetts
2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
3Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland
4Division of Neurology, Department of Pediatrics, Nemours Children’s Hospital, Orlando, Florida
5Department of Paediatric Neurology, Catholic University, Rome, Italy
6Departments of Neurology and Pediatrics, Columbia University Irving Medical Center, New York, New York
7Department of Neurology and Neurosurgery and Department of Pediatrics, McGill University, Montreal, Quebec, Canada
8Department of Clinical and Molecular Genetics and Rare Diseases Unit, Hospital Vall d0Hebron and Centro de Investigacıon Biomedica en Red
Enfermedades Raras (CIBERER), Barcelona, Spain
9Royal Children’s Hospital, Murdoch Children’s Research Institute and University of Melbourne, Melbourne, Australia
10Dubowitz Neuromuscular Centre, University College London, London, United Kingdom
11NIHR Great Ormond Street Hospital Biomedical Research Centre, London, United Kingdom
12Biogen, Cambridge, Massachusetts
13Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland
Correspondence
Basil T. Darras, Department of Neurology,
Boston Children’s Hospital and Harvard
Medical School, 330 Longwood Avenue,
Fegan, 11th Floor, Boston, MA 02115, USA.
Tel: 617 355 8235; Fax: 617 730 0279;
E-mail: Basil.Darras@childrens.harvard.edu
Funding Information
This study was sponsored by Biogen
(Cambridge, MA, USA).
Received: 21 March 2019; Accepted: 22
March 2019
Annals of Clinical and Translational
Neurology 2019; 6(5): 932–944
doi: 10.1002/acn3.779
*Employee of Biogen at the time of the
study/manuscript preparation.
Abstract
Objective: To evaluate plasma phosphorylated neurofilament heavy chain
(pNF-H) as a biomarker in spinal muscular atrophy (SMA). Methods: Levels
of pNF-H were measured using the ProteinSimple platform in plasma sam-
ples from infants with SMA enrolled in ENDEAR (NCT02193074) and
infants/children without neurological disease. Results: Median pNF-H plasma
level was 167.0 pg/mL (7.46–7,030; n = 34) in children without SMA (aged
7 weeks–18 years) and was higher in those aged < 1 versus 1–18 years
(P = 0.0002). In ENDEAR participants with infantile-onset SMA, median
baseline pNF-H level (15,400 pg/mL; 2390–50,100; n = 117) was ~10-fold
higher than that of age-matched infants without SMA (P < 0.0001) and ~90-
fold higher than children without SMA (P < 0.0001). Higher pretreatment
pNF-H levels in infants with SMA were associated with younger age at symp-
tom onset, diagnosis, and first dose; lower baseline Children’s Hospital of
Philadelphia Infant Test of Neuromuscular Disorders score; and lower per-
oneal compound muscle potential amplitude. Nusinersen treatment was asso-
ciated with a rapid and greater decline in pNF-H levels: nusinersen-treated
infants experienced a steep 71.9% decline at 2 months to 90.1% decline at
10 months; sham control–treated infants declined steadily by 16.2% at
2 months and 60.3% at 10 months. Interpretation: Plasma pNF-H levels are
elevated in infants with SMA. Levels inversely correlate with age at first dose
and several markers of disease severity. Nusinersen treatment is associated
with a significant decline in pNF-H levels followed by relative stabilization.
Together these data suggest plasma pNF-H is a promising marker of disease
activity/treatment response in infants with SMA.
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Introduction
Spinal muscular atrophy (SMA) is a severe autosomal
recessive inherited disorder characterized by degeneration
of alpha motor neurons and consequent muscle weak-
ness.1 It is caused by biallelic loss-of-function mutations
of the survival motor neuron 1 gene (SMN1). Embryonic
lethality that would occur due to a complete absence of
SMN protein is rescued by the presence of a variable
number of copies of a paralogous gene, SMN2. However,
the majority of SMN protein produced by SMN2 is only
partially functional due to alternative splicing that mostly
encodes a truncated transcript and protein.1 Nusinersen,
the first approved treatment for SMA, acts to increase
functioning SMN protein by altering SMN2 pre-messen-
ger RNA splicing to favor production of a full-length
form that encodes normal SMN protein.2,3
Given the potential to significantly alter the disease
course with treatment,4,5 strategies to establish an early
diagnosis, assess disease activity, and monitor treatment
response have become key disease management priorities.
Historically, diagnosis of SMA has generally followed
development of symptomatic weakness, which varies in
severity and manifests only after accrual of substantial
pathology.1 Identification of biallelic SMN1 deficiency is
followed by assessment of SMN2 copy number genotype,
which is an important but imperfect predictor of
untreated clinical course.1,6 As a predictive genetic bio-
marker, SMN2 copy number is, along with other less sen-
sitive measures under investigation, of no value as a
marker of ongoing disease activity or response to treat-
ment.7 Thus, there is now an urgent need for biomarkers
of disease activity and treatment response to scale and
monitor therapy, and to enable more efficient future clin-
ical trial design.
Neurofilament (NF) proteins have been investigated as
potential biomarkers for several disorders characterized by
axonal injury and degeneration.8 These intermediate fila-
ments are uniquely expressed in neurons, and when
released into extracellular fluid upon perikaryal or axonal
degeneration, can be detected in cerebrospinal fluid (CSF)
and blood.8,9 NFs comprise three proteins differentiated
by molecular weight, light (NF-L), medium, and heavy
(NF-H).8,9 About 80% of axonal NFs are highly phospho-
rylated, conferring resistance to protein degradation.9,10
Elevated concentrations of NF-H have been detected in
blood and/or CSF in disorders such as amyotrophic lat-
eral sclerosis (ALS), multiple sclerosis (MS), Alzheimer’s
disease, and Parkinson’s disease.8,11–16 Elevated concentra-
tions of NF-L have been documented in Alzheimer’s
disease, ALS, MS, Charcot-Marie-Tooth disease, and
adult-onset leukoencephalopathy with axonal spheroids
and pigmented glia.8,11,12,15–21 In the absence of specific
disease-modifying therapy, the value of NF elevations as a
biomarker remains unclear.8
To determine the value of plasma phosphorylated
NF-H (pNF-H) as a disease-sensitive pharmacodynamic/
response biomarker in SMA, we measured pNF-H con-
centrations in sham control– and nusinersen-treated
infants with SMA enrolled in the ENDEAR trial com-
pared with infants and children without SMA. Further, in
the ENDEAR SMA cohort, we examined pNF-H concen-
trations over time in sham control– and nusinersen-trea-
ted participants, as well as the relationship between
baseline pNF-H concentration and pretreatment markers
of disease severity.4
Methods
Study samples
ENDEAR participants
ENDEAR (NCT02193074) was a phase III, randomized,
double-blind, sham procedure–controlled study that
assessed the efficacy and safety of nusinersen in partici-
pants with infantile-onset SMA (aged < 6 months at
symptom onset, with 2 SMN2 copies, and considered
most likely to develop SMA Type I). As reported previ-
ously, participants aged ≤ 7 months at screening were
randomized 2:1 to nusinersen (12 mg scaled equivalent
dose) or sham control.4 Nusinersen was administered as a
loading dose on days 1, 15, 29, and 64, followed by main-
tenance dosing every 4 months (on days 183 and 302).
Baseline demographic and clinical data were collected,
including Hammersmith Infant Neurological Examination
Section 2 (HINE-2) motor milestones score, Children’s
Hospital of Philadelphia Infant Test of Neuromuscular
Disorders (CHOP INTEND) score, and peroneal and
ulnar nerve compound muscle action potential (CMAP)
amplitudes.4 Following a prespecified interim analysis that
demonstrated a benefit-risk assessment in favor of nusin-
ersen, the trial was terminated early. All participants were
invited to complete an end-of-trial visit, at which point
81 of the 121 individuals dosed had been on study
for ≥ 183 days, and 48 had completed treatment to the
day 302 visit.
Plasma samples were collected on days 1, 2, 29, 64,
183, and 302. Plasma was then extracted, and samples
were stored frozen at 70°C then diluted at the mini-
mum required using assay dilution buffer (available as
part of the assay kit) prior to use.
Approval for the trial was provided by an ethics com-
mittee at each participating institution, and it was con-
ducted in accordance with the International Conference
ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 933
B. T. Darras et al. Neurofilament Levels in Infants with SMA
on Harmonisation guidelines for Good Clinical Practice
and the World Medical Association Declaration of Hel-
sinki. Written informed consent for each participant was
provided by their health care proxy.4
Individuals without SMA
pNF-H testing was also conducted in samples from indi-
viduals without SMA or other neurodegenerative diseases.
Twenty-nine samples were from Boston Children’s Hospi-
tal. Reasons for sample collection are not available due to
confidentiality, but all samples were from individuals aged
1 day to 18 years, with International Statistical Classifica-
tion of Diseases and Related Health Problems, 10th revi-
sion code(s) for a well-child visit, with no known
neurological or musculoskeletal disorders, no history of
other chronic illness, normal values for hemoglobin A1c
and complete blood count tests, and no other grossly
abnormal laboratory values. A further five samples were
purchased from Analytical Biological Services Inc. and
were from healthy donors aged 4 to 17 years.
Dipotassium ethylenediaminetetraacetic acid plasma
was collected and centrifuged at 3000 9 g for 7 min, ali-
quoted into cryovials, frozen at 20°C, and shipped to
Biogen on dry ice. Individual samples were not retested
for the purposes of these evaluations.
pNF-H measurement
pNF-H concentrations in plasma were measured using a
pNF-H enzyme-linked lectin assay from ProteinSimple
according to the manufacturer’s instructions.22 The Sim-
ple Plex enzyme-linked lectin assay performs immunoas-
says in a microfluidic cartridge. Samples are loaded into
the cartridge wells and then run through a microfluidic
channel containing three glass nanoreactors coated with a
capture antibody against pNF-H. Plates are washed and a
detection reagent added that binds to pNF-H and gener-
ates 1 relative fluorescence unit signal per glass nanoreac-
tor. The relative fluorescence unit is used to interpolate
the concentration from a factory-generated and calibrated
standard curve (5-PL fit with 1/y2 weighting) and
reported in pg/mL. The results presented are statistical
means and do not imply that the assay is capable of the
sensitivity or precision necessary to generate results > 3
significant figures.
Objectives and endpoints
The primary objectives were to assess plasma pNF-H
levels in individuals without SMA; using samples from
ENDEAR, to compare baseline plasma pNF-H levels with
disease characteristics, including age at symptom onset,
age at SMA diagnosis, age at first dose, gestational age,
baseline weight, disease duration at baseline, baseline
CHOP INTEND score, baseline HINE-2 motor milestones
score, and baseline ulnar and peroneal nerve CMAP
amplitudes; and to compare plasma pNF-H levels among
individuals without SMA with those in the group with
infantile-onset SMA. Additional objectives were to evalu-
ate longitudinal plasma pNF-H levels and percentage
change from baseline over time in the nusinersen and
sham control treatment groups from ENDEAR.
Statistical analyses
The pNF-H analysis population from ENDEAR com-
prised trial participants who were randomized and
received ≥ 1 dose of either nusinersen or sham control.
Baseline pNF-H is defined as the most recent nonmissing
measurement collected before the first dose or day 1. The
pNF-H concentration levels were log transformed for sta-
tistical testing based on the data distribution evaluated.
Summary statistics were used to analyze the data from
individuals without SMA; the Wilcoxon rank-sum test
was used to compare levels by age (<1 vs. 1–18 years) in
individuals without SMA, and baseline levels in partici-
pants with infantile-onset SMA versus those without
SMA. Spearman’s rank correlation was used to assess the
association between pNF-H levels and age in individuals
without SMA. Pearson correlation coefficients were used
to evaluate associations between baseline pNF-H and
other baseline characteristics and SMA history. Median
pNF-H concentration was used to compare the baseline
characteristics and clinical assessments between groups of
participants with SMA with baseline pNF-H lower and
higher than the median pNF-H value. For continuous
variables, Student’s 2-sample t test was applied to test
continuous values and Fisher’s exact test was used for
proportion values; 95% confidence intervals (CIs) for dif-
ference in continuous variables are derived from Stu-
dent’s 2-sample t test. If the test on the equality of
variance failed to reject the null hypothesis at
alpha = 0.05, a pooled-variance t test was applied; if the
test on the equality of variance rejected the null hypothe-
sis, Satterthwaite was applied. 95% CIs for the difference
in proportion are the exact unconditional CIs.
To evaluate the pNF-H change over time, both absolute
pNF-H and percentage change from baseline were sum-
marized by treatment cohort at each time point. The per-
centage change from baseline was defined as: (change
value from baseline/baseline value) 9 100.
An imputed pNF-H concentration of 7.46 pg/mL, the
level of the assay sensitivity, was used for concentrations
below the limit of quantification (BLQ). For participants
with a baseline pNF-H concentration that was BLQ,
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percentage change from baseline could not be determined
and was denoted as “NA”. The linear mix model was
applied to determine whether there was any difference in
the change in pNF-H values over time between the nusin-
ersen- and sham control–treated groups; the analysis of
variance test was used to determine the marginal effect of
treatment assignment on mean pNF-H values. The Wil-
coxon rank-sum test was used to compare percentage
change from baseline at study visit between groups at the
time point of interest.
The statistical software SAS and R were used for these
analyses. Requests for the data supporting this manuscript
should be submitted to the Biogen Clinical Data Request
Portal (www.biogenclinicaldatarequest.com).
Results
Plasma pNF-H levels in infants and children
without SMA
Plasma pNF-H levels were evaluated in samples from 34
individuals without SMA or other neurodegenerative dis-
eases who had a median (range) age of 6.5 years
(7 weeks–18 years); 20 of the individuals were female and
14 male. Overall, mean (standard error [SE]) plasma
pNF-H level was 563.6 (231.04) pg/mL, with a median
(range) of 167.0 (BLQ–7,030) pg/mL. The highest pNF-H
levels were found in the youngest infants: median (range)
in those aged < 1 year was 1510 pg/mL (579–7030;
n = 6) compared with 124.5 pg/mL (BLQ–395; n = 28)
in those aged 1 to 18 years (P = 0.0002; Fig. 1) and
appeared to decline with age (Spearman’s rank
correlation, –0.72; P < 0.0001). Importantly, these plasma
pNF-H values were comparable with those obtained in
previously published studies (Table 1),11,22–30 although it
should be noted that varying methods and assays were
used.
Plasma pNF-H levels in symptomatic infants
with SMA
The participants with infantile-onset SMA (n = 121)
were, by inclusion criteria to the ENDEAR trial, symp-
tomatic at enrollment; mean (range) age at symptom
onset was 8.4 (1–20) weeks, mean (range) disease dura-
tion was 13.4 (0.0–25.9) weeks, mean (range) age at first
dose was 169.2 (30–262) days, and 55% were female.
Functional and electrophysiologic measures of disease
severity included a mean (standard deviation [SD])
baseline total HINE-2 score of 1.37 (1.1), total CHOP
INTEND score of 27.2 (8.0), peroneal CMAP amplitude
of 0.353 (0.30) mV, and ulnar CMAP amplitude of
0.226 (0.17) mV. Pretreatment plasma pNF-H levels
were available from 117 participants and ranged from
2390 to 50,100, with a median pNF-H level of
15,400 pg/mL. This is ~10 times the median pNF-H level
in nonneurological disease controls aged < 1 year
(P < 0.0001). Of the symptomatic infants with SMA, 105/
117 (90%) had a baseline pNF-H level > 7030 pg/mL, the
highest level observed in an individual without SMA. The
median baseline pNF-H concentration of the nusinersen
and sham control groups was not statistically different:
15,200 pg/mL (2390–37,300; n = 77) versus 17,150 pg/mL
(4900–50,100; n = 40; P = 0.2828).
Analyses of baseline pNF-H and baseline disease char-
acteristics showed inverse correlations with several mark-
ers of disease severity, including age at SMA diagnosis
(r = 0.25; probability >r under H0, rho = 0.0064;
n = 117), age at symptom onset (r = 0.20; 0.0344;
n = 117), age at first dose (r = 0.24; 0.0106; n = 117),
and baseline CHOP INTEND score (r = 0.30; 0.0012;
n = 117), although large variations were observed among
individuals for each of these variables. Similar correlations
were observed with gestational age plus age at symptom
onset (r = 0.19; 0.0376; n = 117), gestational age plus
age at SMA diagnosis (r = 0.24; 0.0080; n = 117), and
gestational age plus age at first dose (r = 0.23; 0.0130;
n = 117). Other measures of disease severity, including
baseline HINE-2 motor milestone score, were not signifi-
cantly correlated (data not shown). Evaluation of baseline
characteristics dichotomized by median plasma pNF-H
concentration identified similar correlations (Table 2).
Change in plasma pNF-H levels over time in
symptomatic infants with SMA
Plasma pNF-H concentration declined over time in both
the nusinersen and sham control groups (Fig. 2A and
B). In the nusinersen-treated arm, the pNF-H concentra-
tion declined more rapidly and to a greater magnitude
before stabilizing at a level below the sham control arm
at any point of the study. In contrast, participants in the
sham control arm experienced a steady and gradual
decline in pNF-H concentration over the study duration.
The greatest difference in mean plasma pNF-H concen-
trations was observed at day 64; there was a 71.9%
reduction compared with baseline in the nusinersen-trea-
ted group and a 16.2% reduction in the sham control
group (Fig. 2A). At the end of the dosing period, pNF-H
levels were 90.1% reduced in nusinersen-treated partici-
pants and 60.3% reduced in the sham control group
(compared with pretreatment levels). Analysis of variance
testing based on the linear mix model indicated a mar-
ginal (average across the individuals) treatment effect on
the difference in the pNF-H decline between the nusin-
ersen- and sham control–treated groups (P < 0.0001 by
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F test); there was also a difference between groups in
percentage change from baseline at day 64 (P < 0.0001
by Wilcoxon rank-sum test). At the end of the dosing
period (mean [range] age, 15.1 [11.6–18.0] months),
absolute pNF-H levels in the nusinersen-treated group
(mean [range], 1465.5 [41–5180] pg/mL; n = 30 at day
Figure 1. Plasma pNF-H levels (single test per sample) in children without spinal muscular atrophy (A) by individual and (B) by age group.
7.46 pg/mL was used as the imputed value if the pNF-H concentration was below the limit of quantification. The box represents the IQR and the
whiskers the minimum and maximum values; the median is shown as a horizontal line within the box and the mean as a+. aThe highest value
recorded in this group (395 pg/mL and designated by a dot) was considered an outlier by statistical analysis as it was greater than 1.5 9 IQR.
IQR = interquartile range; pNF-H = phosphorylated neurofilament heavy chain.
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302) were lower than in the sham control group (5664.7
[1100–10,600] pg/mL; n = 15), but remained elevated
compared with age-matched infants without SMA
(aged < 1 year: mean [range], 2516.3 [579–7030] pg/mL;
n = 6; aged 1–5 years: mean [range], 188.3 [7–386
pg/mL]; n = 8). At day 302, 2 (13%) participants in the
sham control group and 22 (73%) in the nusinersen-
treated group had pNF-H levels < 1940 pg/mL, a level
that 75% of individuals without SMA aged < 2 years
(n = 9) were below. The levels of pNF-H from individ-
ual participants in ENDEAR (by treatment group) are
shown in Figure 3.
Discussion
Novel SMN-enhancing treatments could substantially
improve the degenerative course of SMA.4,5 However, fur-
ther optimization of treatment necessitates a sensitive and
rapid pharmacodynamic/response biomarker of disease
activity. Here we show that plasma pNF-H levels are ele-
vated in participants with infantile-onset SMA versus age-
matched controls; that the magnitude of pretreatment
pNF-H levels correlates with clinical characteristics pre-
dictive of disease severity; and that nusinersen treatment
causes a steep decline within 2 months of initiation of
nusinersen followed by relative stabilization of pNF-H
levels.
Recent advances in detection technologies have
enabled reliable quantification of neuronal NFs released
into interstitial fluids during central or peripheral ner-
vous system degeneration.31 Although several different
assays have been used previously to measure pNF-H,
our data in nonneurological disease controls are compa-
rable with those previously published (Table 1). Few of
these studies have examined pNF-H levels in infants
aged < 1 year, and none have used the assay platform
Table 1. Blood pNF-H concentrations in healthy controls in previously published studies.
Reference N Age
Mean pNF-H
Concentration
Median pNF-H
Concentration Assay Used
Reason for
Study/
Disease Being
Investigated
Pironkova
et al.23
20 0 (cord blood) 136.8  53.9 pg/mL – BioVendor Congenital heart
surgery
Morel
et al.24
15 (vaginal
delivery)
7 (cesarean
section)
2 days 107.9  54.3 pg/mL
120.2  43.4 pg/mL
107.0 pg/mL
(IQR, 76–126.3)
142.3 pg/mL
(IQR, 74.6–154.4)
In-house assay
(MSD platform)
Neuronal injury
and cerebral
oxygenation
Douglas-
Escobar
et al.25
14 ≤3 days – 15 pg/mL
(range, 70–460)
In-house
assay (ELISA)
Hypoxic-ischemic
encephalopathy
Matsushige
et al.26
28 Median 1.0 years
(range 0.1–5.6)
~1000 pg/mL (graph
only)
– EnCor Prolonged febrile
seizures
Weydt
et al.11
19 Median 33.0
(IQR, 25.0–44.0)
Results in CSF only – BioVendor Amyotrophic
lateral sclerosis
Petzold
et al.28
14 Median 36 years
(IQR, 30–43)
– 5 pg/mL
(IQR, 0–94)
In-house
assay (ELISA)
Acute optic
neuritis
Petzold
et al.27
14 36 (24–59) years – 4.5 pg/mL
(range, 0–41)
In-house
assay (ELISA)
Multiple sclerosis
McCombe
et al.16,29
59 Mean 48 years
(range 21–95)
– 380 pg/mL
(range, 0–1025)
EnCor Amyotrophic
lateral sclerosis
Boylan
et al.30
19 Median 60 years
(range 27–79)
≤60 years
>60 years
– 170 pg/mL (25th,
75th percentile, 130,
250)
140 (120, 170)
250 (180, 310)
In-house
assay (ELISA)
Amyotrophic
lateral sclerosis
Protein
Simple
assay
product
sheet22
10
10
10
NA Serum 222  184 pg/mL
EDTA plasma
226  193 pg/mL
Heparin plasma
220  181 pg/mL
– ProteinSimple –
CSF, cerebrospinal fluid; EDTA, ethylenediaminetetraacetic acid; ELISA, enzyme-linked immunosorbent assay; IQR, interquartile range; MSD,
MesoScale Discovery; NA, not applicable; pNF-H, phosphorylated neurofilament heavy chain.
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employed in this study. Interestingly, we observed higher
pNF-H levels in nonneurological disease control infants
aged < 1 year than in older children, whose levels were
similar to those previously reported in adults. Higher
levels of plasma pNF-H in control infants may reflect
ongoing normal developmental neuronal pruning pro-
cesses such as programmed cell death, remodeling of
polyneuronal muscle fiber innervation, or any combina-
tion of these.32 The role of other NFs, such as NF-L,
will be important to evaluate in future studies. Further-
more, the half-life of NFs in interstitial fluids is not
known, but phosphorylation confers degradation resis-
tance; pNFs have a much longer half-life than the over-
all NF population.33 Because some studies suggest that
the half-life of NF within axons may be up to
8 months,8 it is possible that the presence of pNF-H in
plasma could reflect release that occurred weeks or
months earlier.
Plasma pNF-H concentrations in infantile-onset SMA
were significantly higher at study baseline (median,
15,400 pg/mL) than in children without SMA
aged < 1 year (median, 1510 pg/mL using the same
assay), or previously reported concentrations in infants/
adults without SMA (Table 1).22–30 Elevation of plasma
NF levels in infants with SMA can be expected given that
human postmortem pathological studies document
degeneration and severe loss of anterior horn cells, ventral
root axons and neuromuscular junction (NMJ) presynap-
tic terminals.32 Similar neurodegenerative events are
apparent in severe SMA mouse models.34 Additionally, in
both human and mouse models, remaining intact presy-
naptic terminal axons at the NMJ contain abnormal accu-
mulation of pNFs, which could result from abnormalities
of NF transport or terminal degradation.32,35 The magni-
tude of elevated baseline plasma pNF-H levels among
infantile-onset SMA participants in ENDEAR is strikingly
Table 2. Baseline characteristics and SMA history by baseline plasma pNF-H concentration (above and below the median).
Baseline pNF-H
Difference, % (95% CI)2 P value3<Median1 ≥Median1
Individuals, n4 58 59
No. (%) in the nusinersen treatment arm5 40 (52) 37 (48)
No. (%) in the sham control treatment arm5 18 (45) 22 (55)
Female, n (%) 32 (55) 33 (56) 0.76 (–18.93 to 17.84) 1.0000
Age of symptom onset, wk, mean (range) 9.5 (3–20) 7.3 (2–19) 2.14 (0.66–3.62) 0.0049
Age at SMA diagnosis, wk, mean (range) 16.02 (4–29) 12.31 (0–30) 3.71 (1.17–6.26) 0.0046
Disease duration, wk, mean (range) 13.8 (0.6–25.9) 13.2 (0–23.1) 0.59 (1.46 to 2.64) 0.5723
Age at first dose, wk, mean (range) 25.8 (7.4–37.4) 22.6 (4.3–33.6) 3.18 (0.59–5.77) 0.0165
Gestational age + age at first dose,
wk, mean (range)
64.8 (46.4–75.1) 61.6 (44.3–73.6) 3.23 (0.58–5.89) 0.0173
Symptoms of SMA, n (%)
Hypotonia 58 (100) 59 (100) 0 (NA–NA) NA
Motor delay 56 (97) 50 (85) 11.81 (6.15 to 29.50) 0.0533
Paradoxical breathing 46 (79) 49 (83) 3.74 (21.28 to 14.61) 0.6428
Pneumonia/respiratory symptoms 18 (31) 18 (31) 0.53 (17.95 to 17.95) 1.0000
Limb weakness 58 (100) 58 (98) 1.69 (16.28 to 19.62) 1.0000
Swallowing abnormalities 26 (45) 26 (44) 0.76 (17.84 to 18.93) 1.0000
Other 12 (21) 22 (37) 16.60 (34.37 to 1.02) 0.0665
Use of ventilator support, n (%) 14 (24) 13 (22) 2.10 (16.28 to 19.62) 0.8290
Total HINE-2 score, mean  SD 1.6  1.30 1.2  0.94 0.40 (0.02 to 0.82) 0.0593
Total CHOP INTEND score, mean  SD 29.49  7.125 25.11  7.850 4.38 (1.63–7.13) 0.0020
Peroneal CMAP amplitude, mean  SD 40  0.328 0.28  0.244 0.12 (0.01–0.23) 0.0353
Ulnar CMAP amplitude, mean  SD 0.21  0.162 0.23  0.164 0.02 (0.08 to 0.05) 0.6259
CHOP INTEND, Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders; CI, confidence interval; CMAP, compound muscle
action potential; HINE-2, Hammersmith Infant Neurological Examination Section 2; pNF-H, phosphorylated neurofilament heavy chain; SD, stan-
dard deviation; SMA, spinal muscular atrophy.
1Median of baseline pNF-H = 15,400 pg/mL.
2The 95% CIs for difference in continuous variables are derived from Student’s 2-sample t test. If the test on the equality of variance fails to reject
the null hypothesis at alpha = 0.05, pooled-variance t test is applied, and if the test on the equality of variance rejects the null hypothesis, Sat-
terthwaite is applied. 95% CIs for difference in proportion are the exact unconditional CIs.
3Results for continuous variables are from Student’s 2-sample t test and results for proportions are from Fisher’s exact test.
4Number of participants in the table refers to participants who have nonmissing baseline pNF-H in either category.
5Percentage is based on the total number of participants in either treatment cohort who have nonmissing baseline pNF-H.
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higher than that reported in other neurological dis-
eases13,27,29,30 with a median pretreatment plasma pNF-H
level of 15,400 pg/mL (range 2390 to 50,100) in the 117
participants with available samples. Measurements of
pNF-H levels in patients with ALS range from 220 to
3140 pg/mL in one study36 and 6.0 to 1024.2 pg/mL in
another,37 and levels in patients with MS range from 0.1
to 2400 pg/mL,13,27 although these studies use different
assays. The trajectory of pNF-H concentration over time
in infantile-onset SMA is also distinctive. In this study,
pNF-H levels declined by ~60% over the 10-month study
period in sham control–treated participants. In contrast,
the median plasma pNF-H levels of symptomatic patients
with ALS remain stable or increase over time,29,30
although rare patients with rapid disease progression
show a decrease in pNF-H.38 The high levels of pNF-H
Figure 2. (A) Mean plasma pNF-H concentration (pg/mL) over time during the ENDEAR trial, and (B) percentage change from baseline in pNF-H
concentration (pg/mL) over time (nusinersen offset left for the purposes of graphic display). The results presented are statistical means and do not
imply that the assay is capable of the sensitivity or precision necessary to generate results > 3 significant figures. pNF-H = phosphorylated
neurofilament heavy chain; SE = standard error.
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measured in infantile-onset SMA participants at baseline
suggest that neurodegeneration is fulminant early on in
the disease. This is consistent with the natural history of
infantile-onset SMA, in which symptoms present within
months of birth and motor function declines by ~50% by
age 3–4 months, during a time when infants would natu-
rally be gaining substantial developmental abilities.39 It is
also consistent with longitudinal electrophysiological stud-
ies of motor unit number in a small group of patients
with infantile-onset SMA who manifested a steep decline
to very low levels within 1 to 2 months.40 The steady
decline in pNF-H levels in sham control–treated partici-
pants with infantile-onset SMA who experienced a pro-
gressive decline of function may represent any of a
number of nonexclusive processes, including death of
motor neurons and/or axons, progressive motor neuron
dysfunction to a nonfunctional but reversible state,
change from an active to subacute disease phase,
decreased production of pNF-H and/or changes in mech-
anisms of pNF-H release, and/or changes in how pNF-H
is synthesized, released, or degraded over developmental
time. These pNF-H changes in the sham control group
further support the well-established hypothesis that neu-
rodegeneration is most active at clinical disease onset.7,41
Further studies will be needed to determine when NF
levels first become elevated in patients with SMA, and the
patterns of NF expression in individuals with later-onset
SMA.
Disease biomarkers can serve many purposes; they can
inform prognosis, signal disease progression, predict
response to therapy, and/or mark a key process of disease
that is influenced by therapy. Baseline correlations
Figure 3. Change in pNF-H concentration for individual participants. (A) pNF-H concentration (pg/mL) over time, and (B) percentage change from
baseline in pNF-H concentration (pg/mL) over time. pNF-H values are presented for study visits that the individual attended and provided a blood
sample. pNF-H = phosphorylated neurofilament heavy chain.
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between pNF-H levels and clinical characteristics indica-
tive of disease severity in the ENDEAR population suggest
that elevated levels of pNF-H may have prognostic value
because they correlate with disease course. The temporal
relationship between onset of release of pNF-H into inter-
stitial fluid and an irreversible step in SMA-associated
neurodegeneration is at present unknowable, because a
cascade of neuronal degenerative steps may precede, coin-
cide, or follow pNF-H release. Nonetheless, the early,
marked elevation of pNF-H suggests that levels may also
be elevated in presymptomatic children, such as those
identified during newborn screening, indicating an under-
lying degenerative process and justifying treatment initia-
tion. In those identified during newborn screening who
have ≥ 4 SMN2 copies, monitoring pNF-H levels may
facilitate decisions on the appropriate time to initiate
therapy to achieve the optimal outcome.42
In most diseases, evaluating NF levels as a marker of
treatment response has been limited by the lack of dis-
ease-modifying therapies. One exception is MS, in which
a decrease of serum NF-L (up to 34% over 12 months)
has been associated with initiation or change in treat-
ment.31 The rapid decline of highly elevated pNF-H levels
following initiation of nusinersen in participants who
later manifested clinical stabilization or improvement rel-
ative to sham control–treated participants strongly sup-
ports pNF-H levels as a pharmacodynamics/response
biomarker for nusinersen and potentially other SMN-tar-
geted therapies. These data suggest nusinersen is suppress-
ing the degenerative disease process via increased
production of full-length SMN protein, thus reducing
ongoing release of pNF-H from SMN-deficient neurons.
This is consistent with the effects previously observed in
severe SMA mouse models where nusinersen was associ-
ated with retained NMJ innervation and increased ante-
rior horn cell survival.43 While decreases in pNF-H were
evident at the first follow-up assessment, the most dra-
matic effect was seen at day 64. This latency may reflect
the time needed for SMN protein levels to accumulate
thus slowing degeneration, time needed to clear irrepara-
bly damaged neurons and axons, half-life of interstitial
pNF-H clearance, or most likely a combination of these.
While the decreases are dramatic, the decline (in individ-
uals likely already diminished in NF-containing neuronal
and axonal volume) to median levels still above levels
among age-matched controls suggests ongoing low levels
of neurodegeneration despite treatment, regional areas of
insufficient treatment, or persistence of very long-lived
species of pNF-H in the blood compartment.
When interpreting these results, consideration should
be given to the relatively small number of samples from
individuals without SMA, a potential floor effect with
pNF-H levels in individuals without SMA, potential
confounding factors for certain baseline disease character-
istics, and lack of sensitivity of certain clinical outcome
scales.
Together, these data support use of plasma pNF-H
concentration as a novel, clinically relevant pharmacody-
namics/response biomarker for nusinersen in SMA, with
the potential to refine recommendations for treatment
initiation/optimization and to allow for differentiation
among SMN-targeting therapies. Further analysis of pre-
and posttreatment plasma and CSF pNF-H and NF-L
levels across SMA populations (e.g., presymptomatic and
later-onset SMA) and evaluation of potential correlations
with efficacy outcomes will contribute to a more compre-
hensive understanding of the potential biomarker func-
tions that NF levels may serve. Furthermore, additional
work in murine models of SMA may identify the relation-
ship between release of pNF-H into the interstitium and
nonreversible steps in the cascade of neurodegeneration.
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